title: "To B(MP-2) or Not To B(MP-2)" or "Much Ado About Nothing": Are Orthobiologics in Tumor Surgery Worth the Risks?
abstract: Geller and colleagues report that adjuvant chemotherapy affected the adequacy of osteosarcoma local surgical control. Exogenous bone morphogenetic protein-2 (BMP-2) did not increase local recurrence, but the limited theoretical benefits of BMP-2 for a subset of patients with osteosarcoma may not justify the systemic and long-term risks.
authors.affiliation: Department of Orthopaedic Surgery, Division of Musculoskeletal Oncology, Cancer Stem Cell Laboratory, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. weiskr@upmc.edu.
authors.forename: Kurt R
authors.initials: KR
authors.lastname: Weiss
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D012516:Osteosarcoma / Q000473:pathology*
chemical_list: D055396:Bone Morphogenetic Protein 2